Cookie Policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read ourPrivacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Terumo to Commence Sales of OFDI Intravascular Imaging System in Europe from July

23/05/2012 - Tokyo, Japan

Debuted at EuroPCR 2012, the World's Leading Cardiovascular Intervention Course

Terumo Corporation (TOKYO: 4543, TSE Section 1) announced today that from this July it will begin a European sales launch of its "LUNAWAVE" OFDI system, an intravascular diagnostic imaging system that applies optical frequency, as well as its "FastView" OFDI imaging catheter. Terumo aims to achieve the revenue of 0.3 billion yen in fiscal year 2012. And, it further aims for 3.5 billion yen in fiscal year 2014 by adding the sales in Japan.

OFDI (Optical Frequency Domain Imaging) employs light applied to the inside of blood vessels from the tip of a catheter, and constructs an intravascular cross-sectional image through a new technology that analyzes the reflection from the vessel walls. It is mainly utilized in coronary intervention to verify the conditions inside blood vessels and confirm the stent apposition. OFDI achieves high image resolution, and is highly expected in its ability to display differences in the tissue characterization of vascular walls, which has been difficult to detect in the past.

Terumo's "LUNAWAVE" OFDI intravascular imaging system was used in live demonstration cases performed at EuroPCR 2012 (May 15-18th), the world's leading cardiovascular intervention course, drawing a considerable amount of interest among numerous physicians.

"The quality of OFDI imaging system was amazing, and it was surpassed conventional diagnostic imaging technologies. I highly expect the system to contribute to providing even safer and more effective coronary interventions", commented Dr. Bernard Chevalier (Clinique Jacque Cartier, France), the physician who used the system in the live demonstration cases.

Terumo will provide a broad lineup of intervention technologies, including not only treatment devices such as drug-eluting stent but also diagnostic imaging system, with the goal to contribute to the safety and reliability of coronary intervention.

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.